業績

2021年（英文）

原著

  1. Akahoshi Y,Arai Y,Nishiwaki S,Mizuta S,Marumo A,Uchida N,Kanda Y,Sakai H,Takada S,Fukuda T,Fujisawa S,Ashida T,Tanaka J,Atsuta Y Kako S:Minimal residual disease (MRD) positivity at allogeneic hematopoietic cell transplantation,not the quantity of MRD,is a risk factor for relapse of Philadelphia chromosome-positive acute lymphoblastic leukemia. Int J Hematol,113(6):832-839,2021.
  2. Akahoshi Y,Arai Y,Nishiwaki S,Tachibana T,Shinohara A,Doki N,Uchida N,Tanaka M,Kanda Y,Shiratori S,Ozawa Y,Shono K,Katayama Y,Tanaka J,Fukuda T,Atsuta Y,Kako S:Newly proposed threshold and validation of white blood cell count at diagnosis for Philadelphia chromosome-positive acute lymphoblastic leukemia: risk assessment of relapse in patients with negative minimal residual disease at transplantation-a report from the Adult Acute Lymphoblastic Leukemia Working Group of the JSTCT. Bone Marrow Transplant,56(11):2842-2848,2021.
  3. Akahoshi Y,Kimura SI,Inamoto Y,Seo S,Muranushi H,Shimizu H,Ozawa Y,Tanaka M,Uchida N,Kanda Y,Katayama Y,Shiratori S,Ota S,Matsuoka KI,Onizuka M,Fukuda T,Atsuta Y,Murata M,Terakura S,Nakasone H:Effect of Cytomegalovirus Reactivation With or Without Acute Graft-Versus-Host Disease on the Risk of Nonrelapse Mortality.Clin Infect Dis,2;73(3):e620-e628,2021.
  4. Akimoto M,Sakurai A,Nishiyama-Fujita Y,Ito C,Aisa Y,Nakazato T:The prognostic value of the Fibrinogen-Albumin Ratio Index in patients with myelodysplastic syndrome and acute myeloid leukemia with myelodysplasia-related changes treated with azacitidine.Ann Hematol,100(4):953-957,2021. 
  5. Akiyama N,Okamura T,Yoshida M,Kimura SI,Yano S,Yoshida I,Kusaba H,Takahashi K,Fujita H,Fukushima K,Iwasaki H,Tamura K,Saeki T,Takamatsu Y,Zenda S:A questionnaire survey on evaluation for penetration and compliance of the Japanese Guideline on Febrile Neutropenia among hematology-oncology physicians and surgeons. Support Care Cancer,29(11):6831-6839,2021.
  6. Ban T,Kikuchi M,Sato GR,Manabe A,Tagata N,Harita K,Nishiyama A,Nishimura K,Yoshimi R,Kirino Y,Yanai H,Matsumoto Y,Suzuki S,Hihara H,Ito M,Tsukahara K,Yoshimatsu K,Yamamoto T,Taniguchi T,Nakajima H,Ito S,Tamura T:Genetic and chemical inhibition of IRF5 suppresses pre-existing mouse lupus-like disease. Nat Commun,12(1):4379,2021.
  7. Fuji S,Hakoda A,Kanda J,Murata M,Terakura S,Inamoto Y,Uchida N,Toya T,Eto T,Nakamae H,Ikegame K,Tanaka M,Kawakita T,Kondo T,Miyamoto T,Fukuda T,Ichinohe T,Kimura T,Atsuta Y,Shintani A,Morishima S:Impact of HLA disparity on the risk of overall mortality in patients with grade II-IV acute GVHD on behalf of the HLA Working Group of Japan Society for Hematopoietic Cell Transplantation. Bone Marrow Transplant,56(12):2990-2996,2021.
  8. Fujimaki K,Hibino Y,Kishimoto K,Watanabe S,Koyama S,Ando T,Kanamori H,Nakajima N:Successful treatment with lenalidomide for relapsed adult T-cell leukemia/lymphoma after cord blood cell transplantation.Blood Cell Therapy,4:44-47,2021.
  9. Harada I,Sasaki H,Murakami K,Nishiyama A,Nakabayashi J,Ichino M,Miyazaki T,Kumagai K,Matsumoto K,Hagihara M,Kawase W,Tachibana T,Tanaka M,Saito T,Kanamori H,Fujita H,Fujisawa S,Nakajima H,Tamura T: Compromised anti-tumor-immune features of myeloid cell components in chronic myeloid leukemia patients.Sci Rep,11(1):18046,2021.
  10. Hirabayashi S,Uozumi R,Kondo T,Arai Y,Kawata T,Uchida N,Marumo A,Ikegame K,Fukuda T,Eto T,Tanaka M,Wake A,Kanda J,Kimura T,Tabuchi K,Ichinohe T,Atsuta Y,Yanada M,Yano S:Personalized prediction of overall survival in patients with AML in non-complete remission undergoing allo-HCT. Cancer Med, 10(13):4250-426,2021.
  11. Imai M,Halfmann PJ,Yamayoshi S,Iwatsuki-Horimoto K,Chiba S,Watanabe T, Nakajima N,Ito M,Kuroda M,Kiso M,Maemura T,Takahashi K,Loeber S,Hatta M,Koga M,Nagai H,Yamamoto S,Saito M,Adachi E,Akasaka O,Nakamura M,Nakachi I,Ogura T,Baba R,Fujita K,Ochi J,Mitamura K,Kato H,Nakajima H,Yagi K,Hattori SI,Maeda K,Suzuki T,Miyazato Y,Valdez R,Gherasim C,Furusawa Y,Okuda M,Ujie M,Lopes TJS,Yasuhara A,Ueki H,Sakai-Tagawa Y,Eisfeld AJ,Baczenas JJ,Baker DA,O'Connor SL,O'Connor DH,Fukushi S,Fujimoto T,Kuroda Y,Gordon A,Maeda K,Ohmagari N,Sugaya N,Yotsuyanagi H,Mitsuya H,Suzuki T,Kawaoka Y:Characterization of a new SARS-CoV-2 variant that emerged in Brazil. Proc Natl Acad Sci U S A,20216;118(27):e2106535118,2021.
  12. Isobe M,Konuma T,Masuko M,Uchida N,Miyakoshi S,Sugio Y,Yoshida S,Tanaka M,Matsuhashi Y,Hattori N,Onizuka M,Aotsuka N,Kouzai Y,Wake A,Kimura T,Ichinohe T,Atsuta Y,Yanada M:Adult Acute Myeloid Leukemia Working Group of the Japan Society for Hematopoietic Cell Transplantation.Single cord blood transplantation for acute myeloid leukemia patients aged 60 years or older: a retrospective study in Japan. Ann Hematol,100(7):1849-1861,2021.
  13. Ito A,Nakano N,Tanaka T,Fuji S,Makiyama J,Inoue Y,Choi I,Nakamae H,Nagafuji K,Takase K,Machida S,Takahashi T,Sawayama Y,Kamimura T,Kato K,Kawakita T,Ogata M,Sakai R,Shiratori S,Uchimaru K,Inamoto Y,Utsunomiya A,Fukuda T:Improved survival of patients with aggressive ATL by increased use of allo-HCT: a prospective observational study.Blood Adv,26:5(20):4156-4166,2021.
  14. Izutsu K,Ando K,Nishikori M,Shibayama H,Teshima T,Kuroda J,Kato K,Imaizumi Y,Nosaka K,Sakai R,Hojo S,Nakanishi T,Rai S:Phase II study of tazemetostat for relapsed or refractory B-cell non-Hodgkin lymphoma with EZH2 mutation in Japa. Cancer Sci,112(9):3627-3635,2021.
  15. Kimura SI,Tamaki M,Okinaka K,Seo S,Uchida N,Igarashi A,Ozawa Y,Ikegame K,Eto T,Tanaka M,Shiratori S,Nakamae H,Sawa M,Kawakita T,Onizuka M,Fukuda T,Atsuta Y,Kanda Y,Nakasone H:Cytomegalovirus reactivation is associated with an increased risk of late-onset invasive aspergillosis independently of grade II-IV acute graft-versus-host disease in allogeneic hematopoietic stem cell transplantation: JSTCT Transplant Complications Working Group. Ann Hematol,100(12):3029-3038,2021.
  16. Konuma T,Kanda J,Kuwatsuka Y,Yanada M,Kondo T,Hirabayashi S,Kako S,Akahoshi Y,Uchida N,Doki N,Ozawa Y,Tanaka M,Eto T,Sawa M,Yoshioka S,Kimura T,Kanda Y,Fukuda T,Atsuta Y,Kimura F:Differential Effect of Graft-versus-Host Disease on Survival in Acute Leukemia according to Donor Type. Clin Cancer Res,27(17):4825-4835,2021.
  17. Konuma T,Kanda J,Yamasaki S,Harada K,Shimomura Y,Terakura S,Mizuno S,Uchida N,Tanaka M,Doki N,Ozawa Y,Nakamae H,Sawa M,Matsuoka KI,Morishige S,Maruyama Y,Ikegame K,Kimura T,Kanda Y,Ichinohe T,Atsuta Y,Yanada M:Single Cord Blood Transplantation Versus Unmanipulated Haploidentical Transplantation for Adults with Acute Myeloid Leukemia in Complete Remission. Transplant Cell Ther,27(4):334.e1-334.e11,2021.
  18. Konuma T,Kondo T,Masuko M,Shimizu H,Shiratori S,Fukuda T,Kato J,Sawa M,Ozawa Y,Ota S,Uchida N,Kanda Y,Kako S,Fujisawa S,Fukushima K,Ichinohe T,Atsuta Y,Yanada M:Adult Acute Myeloid Leukemia Working Group of the Japan Society for Hematopoietic Cell Transplantation: Prognostic value of measurable residual disease at allogeneic transplantation for adults with core binding factor acute myeloid leukemia in complete remission. Bone Marrow Transplant,56(11):2779-2787,2021.
  19. Kunimoto H,Nakajima H:TET2: A cornerstone in normal and malignant hematopoiesis.Cancer Sci,112(1):31-40,2021.
  20. Kurosawa S,Kaito S,Uchida N,Fukuda T,Doki N,Mori T,Hasegawa Y,Takada S,Sakaida E,Tanaka M,Ikegame K,Kanda J,Atsuta Y,Kako S:Allogeneic hematopoietic stem cell transplantation for adult patients with B-cell acute lymphoblastic leukemia with high hyperdiploidy: a retrospective nationwide study.Leuk Lymphoma,62(10):2514-2520,2021.
  21. Kurosawa S,Mizuno S,Arai Y,Masuko M,Kanda J,Kohno K,Onai D,Fukuda T,Ozawa Y,Katayama Y,Tanaka M,Ikegame K,Uchida N,Eto T,Ota S,Tanaka J,Ichinohe T,Atsuta Y,Yanada M:Syngeneic hematopoietic stem cell transplantation for acute myeloid leukemia: a propensity score-matched analysis.Blood Cancer J,11(9):159,2021.
  22. Kurosawa S,Yamaguchi T,Mori A,Matsuura T,Mori T,Tanaka M,Kondo T,Umemoto Y,Goto H,Yoshioka S,Machida S,Sato T,Katayama Y,Kato S,Shono K,Mizuno I,Fujiwara SI,Kohno A,Takahashi M,Fukuda T:Resignation and return to work in patients receiving allogeneic hematopoietic cell transplantation close up. J Cancer Surviv,2021.
  23. Mizuno S,Takami A,Kawamura K,Arai Y,Kondo T,Kawata T,Uchida N,Marumo A,Fukuda T,Tanaka M,Ozawa Y,Yoshida S,Ota S,Takada S,Sawa M,Onizuka M,Kanda Y,Ichinohe T,Atsuta Y,Yanada M:Allogeneic Hematopoietic Cell Transplantation for Adolescent and Young Adult Patients with Acute Myeloid Leukemia. Transplant Cell Ther,27(4):314.e1-314.e10,2021.
  24. Mori T,Saburi M,Hagihara M,Mori M,Yamazaki R,Kato J:Long-term remission of cryopyrin-associated periodic syndrome after allogeneic haematopoietic stem cell transplantation. Ann Rheum Dis,80(4):542-543,2021.
  25. Morishima S,Fukuda T,Doki N,Mori T,Onizuka M,Kawakita T,Kato C,Ozawa Y,Tanaka M,Kurokawa M,Kamimura T,Inoue M,Tanaka J,Ichinohe T,Atsuta Y,Morishima Y:HLA Working Group of the Japan Society for Hematopoietic Cell Transplantation. Individual HLAs influence immunological events in allogeneic stem cell transplantation from HLA-identical sibling donors. Bone Marrow Transplant,56(3):646-654,2021.
  26. Murakami K,Kurotaki D,Kawase W,Soma S,Fukuchi Y,Kunimoto H,Yoshimi R,Koide S,Oshima M,Hishiki T,Hayakawa N,Matsuura T,Oda M,Yanagisawa K,Kobayashi H,Haraguchi M,Atobe Y,Funakoshi K,Iwama A,Takubo K,Okamoto S,Tamura T,Nakajima H:OGT Regulates Hematopoietic Stem Cell Maintenance via PINK1-Dependent Mitophagy. Cell Rep,34(1):108579,2021.
  27. Murakami K,Sasaki H,Nishiyama A,Kurotaki D,Kawase W,Ban T,Nakabayashi J, Kanzaki S,Sekita Y,Nakajima H,Ozato K,Kimura T,Tamura T:A RUNX-CBFβ- driven enhancer directs the Irf8 dose-dependent lineage choice between DCs and monocytes.Nat Immunol,22(3):301-311,2021.
  28. Murai K,Ureshino H,Kumagai T,Tanaka H,Nishiwaki K,Wakita S,Inokuchi K,Fukushima T,Yoshida C,Uoshima N,Kiguchi T,Mita M,Aoki J,Kimura S,Karimata K,Usuki K,Shimono J,Chinen Y,Kuroda J,Matsuda Y,Nakao K,Ono T,Fujimaki K,Shibayama H,Mizumoto C,Takeoka T,Io K,Kondo T,Miura M,Minami Y,Ikezoe T,Imagawa J,Takamori A,Kawaguchi A,Sakamoto J,Kimura S:Low-dose dasatinib in older patients with chronic myeloid leukaemia in chronic phase (DAVLEC): a single-arm,multicentre,phase 2 trial.Lancet Haematol,8: e902-e911,2021.
  29. Nakajima H:Molecular Pathogenesis and Treatment of Myelodysplastic Syndromes. Intern Med,60(1):15-23. doi: 10.2169/Internal Medicine,4214-19,2021.
  30. Nakajima H,Murakami K:O-GlcNAcylation: Implications in normal and malignant hematopoiesis.Exp Hematol,101-102:16-24,2021.
  31. Nakasone H,Kako S,Mori T,Takahashi S,Onizuka M,Fujiwara SI,Sakura T,Sakaida E,Yokota A,Aotsuka N,Hagihara M,Tsukada N,Hatta Y,Usuki K,Watanabe R,Gotoh M,Fujisawa S,Yano S,Kanamori H,Okamoto S,Kanda Y:Stopping tyrosine kinase inhibitors started after allogeneic HCT in patients with Philadelphia chromosome-positive leukemia. Bone Marrow Transplant,56(6):1402-1412,2021. 
  32. Nakasone H,Kako S,Tachibana T,Tanaka M,Onizuka M,Takahashi S,Yokota A,Fujiwara SI,Sakura T,Sakaida E,Fujisawa S,Yamazaki R,Gotoh M,Hagihara M,Aotsuka N,Tsukada N,Hatta Y,Shimizu H,Usuki K,Watanabe R,Mori T,Yano S,Kanamori H,Kanda Y:Novel Indicators of Transplant Outcomes for PhALL: Current Molecular-Relapse-Free Survival.Transplant Cell Ther,27(9):800.e1-800.e8,2021.
  33. Nakamura M,Arai Y,Hirabayashi S,Kondo T,Doki N,Uchida N,Fukuda T,Ozawa Y,Tanaka M,Sawa M,Katayama Y,Kanda Y,Shiratori S,Nakamae H,Yoshioka S,Onizuka M,Ichinohe T,Atsuta Y,Kako S:Residual disease is a strong prognostic marker in patients with acute lymphoblastic leukaemia with chemotherapy-refractory or relapsed disease prior to allogeneic stem cell transplantation.Br J Haematol,194(2):403-413,2021.
  34. Nakazato T,Hagihara M,Sahara N,Tamai Y,Ishii R,Tamaki S,Wake A,Tajika K,Sakai R,Kobayashi T,Hua J,Inoue M,Aisa Y,Fujisawa S,Miyazaki K,Irie S,Tanaka E,Higashihara M:Phase II clinical trial of personalized VCD-VTD sequential therapy using the Vulnerable Elders Survey-13 (VES-13) for transplant-ineligible patients with newly diagnosed multiple myeloma.Ann Hematol,100(11):2745-2754,2021.
  35. Nishiwaki S,Akahoshi Y,Mizuta S,Shinohara A,Hirabayashi S,Noguchi Y,Fukuda T,Uchida N,Tanaka M,Onizuka M,Ozawa Y,Ota S,Shiratori S,Onishi Y,Kanda Y,Sawa M,Tanaka J,Atsuta Y,Kako S:Measurable residual disease affects allogeneic hematopoietic cell transplantation in Ph+ ALL during both CR1 and CR2.Blood Adv,5(2):584-592,2021.
  36. Nukui J,Takahashi H,Tokunaga M,Suzuki T,Suzuki M,Yokose T,Nakamura N,Sakai R,Nakajima H:Successful treatment with brentuximab vedotine for a patient with very late relapse of limited stage classic Hodgkin lymphoma.Int Cancer Conf J,15:11(1):27-30,2021.
  37. Numata A,Sakai R,Arakaki H,Ishiyama Y,Koyama M,Takasaki H,Suzuki M,Yokose T,Yamada T,Yasui K,Yoshida T,Miyashita K,Fujisawa S,Nakamura N,Nakajima H: Simultaneous Malignancy of Primary Splenic Angiosarcoma and Low Grade B-cell Lymphoma.Hematology and Oncology:Current Research,2021.
  38. Sakamoto Y,Isono H,Enoki Y,Taguchi K,Miyazaki T,Kunimoto H,Koike H,Hagihara M,Matsumoto K,Nakajima H,Sahashi Y,Matsumoto K:Population Pharmacokinetic Analysis and Dosing Optimization of Prophylactic Fluconazole in Japanese Patients with Hematological Malignancy.J Fungi (Basel),16(7):975,2021.
  39. Shimomura Y,Hara M,Hirabayashi S,Kondo T,Mizuno S,Uchida N,Mukae J,Kawakita T,Fukuda T,Kanda Y,Ota S,Ozawa Y,Eto T,Maruyama Y,Tanaka M,Nakano N,Kimura T,Ichinohe T,Atsuta Y,Yanada M:Comparison of fludarabine,a myeloablative dose of busulfan,and melphalan vs conventional myeloablative conditioning regimen in patients with relapse and refractory acute myeloid leukemia in non-remission status. Bone Marrow Transplant,56(9):2302-2304,2021.
  40. Shiratori S,Sugita J,Ota S,Kasahara S,Ishikawa J,Tachibana T,Hayashi Y,Yoshimoto G,Eto T,Iwasaki H,Harada M,Matsuo K,Teshima T:Japan Study Group for Cell Therapy and Transplantation (JSCT). Low-dose anti-thymocyte globulin for GVHD prophylaxis in HLA-matched allogeneic peripheral blood stem cell transplantation. Bone Marrow Transplant,56(1):129-136,2021.
  41. Takahashi H,Sakai R,Sakuma T,Matsumura A,Miyashita K,Ishii Y,Nakajima Y,Numata A,Hattori Y,Miyazaki T,Hashimoto C,Koharazawa H,Takemura S,Taguchi J,Fujimaki K,Fujita H,Nakajima H:Comparison of Clinical Features Between Primary and Secondary Breast Diffuse Large B Cell Lymphoma: A Yokohama Cooperative Study Group for Hematology Multicenter Retrospective Study. Indian J Hematol Blood Transfus,37(1):60-66,2021.
  42. Tachibana T,Kanda J,Ishizaki T,Najima Y,Tanaka M,Doki N,Fujiwara SI,Kimura SI,Onizuka M,Takahashi S,Saito T,Mori T,Fujisawa S,Sakaida E,Miyazaki T,Aotsuka N,Gotoh M,Watanabe R,Shono K,Usuki K,Tsukada N,Kanamori H,Kanda Y,Okamoto S: Kanto Study Group for Cell Therapy (KSGCT): Clinical Benefits of Preconditioning Intervention in Patients with Relapsed or Refractory Acute Myelogenous Leukemia Who Underwent Allogeneic Hematopoietic Cell Transplantation: A Kanto Study of Group for Cell Therapy Multicenter Analysis. Transplant Cell Ther,27(1):70.e1-70.e8,2021.
  43. Tachibana T,Kanda J,Ishizaki T,Najima Y,Tanaka M,Doki N,Fujiwara SI,Kimura SI,Onizuka M,Takahashi S,Saito T,Mori T,Fujisawa S,Sakaida E,Miyazaki T,Aotsuka N,Gotoh M,Watanabe R,Shono K,Kanamori H,Kanda Y,Okamoto S:Kanto Study Group for Cell Therapy (KSGCT): Pre-conditioning intervention in patients with relapsed or refractory acute lymphoblastic leukemia who underwent allogeneic hematopoietic cell transplantation: a KSGCT multicenter retrospective analysis. Ann Hematol,100(11):2763-2771,2021.
  44. Teshigawara-Tanabe H,Hagihara M,Matsumura A,Takahashi H,Nakajima Y,Miyazaki T,Kamijo A,Yamazaki E,Fujimaki K,Matsumoto K,Nakajima H:Passenger lymphocyte syndrome after ABO-incompatible allogeneic hematopoietic stem cell transplantation; dynamics of ABO allo-antibody and blood type conversion. Hematology,26(1):835-839,2021. 
  45. Yamayoshi S,Yasuhara A,Ito M,Akasaka O,Nakamura M,Nakachi I,Koga M,Mitamura K,Yagi K,Maeda K,Kato H,Nojima M,Pattinson D,Ogura T,Baba R,Fujita K,Nagai H,Yamamoto S,Saito M,Adachi E,Ochi J,Hattori SI,Suzuki T,Miyazato Y,Chiba S,Okuda M,Murakami J,Hamabata T,Iwatsuki-Horimoto K,Nakajima H,Mitsuya H,Omagari N,Sugaya N,Yotsuyanagi H,Kawaoka Y:Antibody titers against SARS-CoV-2 decline,but do not disappear for several months.EClinicalMedicine,32:100734,2021.
  46. Yanada M,Konuma T,Mizuno S,Saburi M,Shinohara A,Tanaka M,Marumo A,Sawa M,Uchida N,Ozawa Y,Onizuka M,Yoshioka S,Nakamae H,Kondo T,Kimura T,Kanda J,Fukuda T,Atsuta Y,Nakasone H,Yano S:Predicting non-relapse mortality following allogeneic hematopoietic cell transplantation during first remission of acute myeloid leukemia. Bone Marrow Transplant,56(2):387-394,2021.
  47. Yanada M,Konuma T,Yamasaki S,Harada K,Iwasaki M,Kobayashi A,Nishijima A,Tanaka M,Uchida N,Nakamae H,Fukuda T,Onizuka M,Ozawa Y,Sawa M,Katayama Y,Yoshioka S,Kimura T,Ichinohe T,Atsuta Y,Kanda J,Yano S:Allogeneic Hematopoietic Cell Transplantation from Alternative Donors in Acute Myelogenous Leukemia: A Comparative Analysis. Transplant Cell Ther,27(12):1005. e1-1005.e8,2021.
  48. Yanada M,Konuma T,Yamasaki S,Kondo T,Fukuda T,Shingai N,Sawa M,Ozawa Y,Tanaka M,Uchida N,Nakamae H,Katayama Y,Matsuoka KI,Kimura T,Kanda Y,Ichinohe T,Atsuta Y,Yano S:Relapse of acute myeloid leukemia after allogeneic hematopoietic cell transplantation: clinical features and outcomes. Bone Marrow Transplant,56(5):1126-1133,2021.
  49. Yanada M,Konuma T,Yamasaki S,Mizuno S,Hirabayashi S,Nishiwaki S,Uchida N,Doki N,Tanaka M,Ozawa Y,Sawa M,Eto T,Kawakita T,Ota S,Fukuda T,Onizuka M,Kimura T,Atsuta Y,Kako S,Yano S:The differential effect of disease status at allogeneic hematopoietic cell transplantation on outcomes in acute myeloid and lymphoblastic leukemia. Ann Hematol,100(12):3017-3027,2021.
  50. Yanada M,Konuma T,Yamasaki S,Kondo T,Fukuda T,Shingai N,Sawa M,Ozawa Y,Tanaka M,Uchida N,Nakamae H,Katayama Y,Matsuoka KI,Kimura T,Kanda Y,Ichinohe T,Atsuta Y,Yano S:Relapse of acute myeloid leukemia after allogeneic hematopoietic cell transplantation: clinical features and outcomes. Bone Marrow Transplant,56(5):126-1133,2021.
  51. Yanada M,Mizuno S,Yamasaki S,Harada K,Konuma T,Tamaki H,Shingai N,Uchida N,Ozawa Y,Tanaka M,Onizuka M,Sawa M,Nakamae H,Shiratori S,Matsuoka KI,Eto T,Kawakita T,Maruyama Y,Ichinohe T,Kanda Y,Atsuta Y,Aoki J,Yano S:Difference in outcomes following allogeneic hematopoietic cell transplantation for patients with acute myeloid leukemia and myelodysplastic syndromes. Leuk Lymphoma,62(14):3411-3419,2021.
  52. Yamauchi N,Maruyama D,Choi I,Atsuta Y,Sakai R,Miyashita K,Moriuchi Y,Tsujimura H,Kubota N,Yamamoto G,Igarashi T,Izutsu K,Yoshida S,Kojima K,Uchida T,Inoue Y,Tsukamoto N,Ohtsuka E,Suzuki S,Inaguma Y,Ichikawa S,Gomyo H,Ushijima Y,Nosaka K,Kurata M,Tanaka Y,Ueda R,Mizokami M,Kusumoto S:Prophylactic antiviral therapy for hepatitis B virus surface antigen-positive patients with diffuse large B-cell lymphoma treated with rituximab-containing chemotherapy．Cancer Sci,112(5):1943-1954,2021.
  53. Yokoyama H,Hirayama M,Takahashi Y,Uchida N,Tanaka M,Onizuka M,Ozawa Y,Onai D,Katsuoka Y,Wake A,Sawa M,Kobayashi H,Maruyama Y,Ozeki K,Kimura T,Kanda J,Fukuda T,Atsuta Y,Terakura S,Morishima S:Altered effect of killer immunoglobulin-like receptor-ligand mismatch by graft versus host disease prophylaxis in cord blood transplantation. Bone Marrow Transplant,56(12):3059-3067,2021.
ページトップへ